GET DAILY SIGNALSTeva Pharmaceutical (TEVA): Q1 2026 Earnings Preview and Pivot to Growth Progress
Key Takeaways
- Analysts expect Q1 2026 revenues of approximately $3.92 billion, a slight decline from $3.89 billion in Q1 2025.
- Consensus non-GAAP EPS estimate stands at $0.57, up from $0.52 in the year-ago quarter.
- Key focus on innovative portfolio growth, including AUSTEDO ($489 million expected), AJOVY ($169 million), and UZEDY ($57 million).
- Generics expected to face headwinds from pricing pressures and Revlimid exclusivity loss; full-year 2026 revenue guidance $16.4–$16.8 billion.
- Teva's "Pivot to Growth" strategy emphasizes innovative medicines amid three years of consecutive revenue growth in 2025 ($17.3 billion).
- Q1 likely seasonally softer, with ramp-up expected in H2 2026 per company outlook.
Earnings Context and Why It Matters
As Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, prepares to report first-quarter 2026 earnings on April 29, followed by a conference call at 8:00 a.m. ET, I'm paying close attention. This will be the first major update since full-year 2025 results, which delivered $17.3 billion in revenues, up 4% year-over-year, largely thanks to innovative products like AUSTEDO surpassing $2 billion annually. Investors like us will want to see clear progress on the "Pivot to Growth" strategy, especially as generics face headwinds, including a $1.1 billion impact from Revlimid in 2026. From what I see, shares have climbed significantly on prior beats—such as the +46% EPS surprise in Q4 2025—so this report could either reinforce momentum or highlight risks from pricing pressures and divestitures like the Japan operations.
Earnings Expectations
Wall Street's consensus from 11 analysts points to Q1 2026 revenues of $3.92 billion, a slight dip from $3.89 billion in Q1 2025, driven by generics pricing erosion and seasonal factors, though partly offset by growth in innovative products. Non-GAAP diluted EPS is expected at $0.57, an improvement from $0.52 a year earlier, bolstered by gross margins around 51% (excluding lenalidomide effects) and savings from the Transformation program.
One thing that stands out are the key metrics for the innovative portfolio: AUSTEDO family global sales at $489 million (with full-year guidance of $2.4–$2.55 billion, +6%–13% YoY), AJOVY at $169 million ($750–$790 million FY), and UZEDY U.S. at $57 million ($250–$280 million FY). Generics, meanwhile, face U.S. declines from a mature portfolio and Revlimid loss of exclusivity (LOE), although non-U.S. operations remain stable. TEVA's full-year 2026 guidance holds steady at $16.4–$16.8 billion in revenues (flat to -2% excluding 2025 milestones), non-GAAP EPS of $2.57–$2.77, and free cash flow (FCF) of $2.0–$2.4 billion, with a focus on net debt reduction. Historically, TEVA has beaten EPS estimates in recent quarters (e.g., +13% in Q1 2025), though stock reactions have ranged from +strong performance to pullbacks tied to guidance.
I also checked this using Tickeron’s AI Screener to see how TEVA stacks up against peers on fundamentals and trends.
Market Reaction and Investor Sentiment
Heading into these earnings, sentiment around TEVA feels cautiously optimistic, supported by the three-year growth streak and strong momentum in the innovative portfolio (up 35% YoY in 2025). Analysts hold a "Moderate Buy" consensus, with price targets around $38, factoring in pipeline catalysts like olanzapine LAI. That said, risks persist from Revlimid headwinds ($1.1 billion FY drag), U.S. generics pricing, and the dips seen after Q4 2025 guidance despite EPS beats. Implied volatility points to a potential ±5–6% post-earnings move, in line with history—like the +20% jump after Q3 2025 on AUSTEDO strength or the -8% drop after Q4 guidance. In my view, the focus will be on beats for key brands and any reaffirmation of the full-year outlook.
Discovering Opportunities with Tickeron’s AI Screener
In my own research process, I rely on Tickeron’s AI Screener, an AI-powered tool for stock and ETF discovery that lets me filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. It scans thousands of stocks and ETFs with customizable filters like industry, market cap, technical indicators, price patterns, and performance metrics—making it far more efficient for spotting trade ideas, trending stocks, breakout candidates, and opportunities than manual screening. I've found it particularly useful for digging into pharma names like TEVA ahead of earnings. If you're looking to streamline your analysis, it's worth exploring.
Forward Outlook and Key Factors to Monitor
After Q1 results, I'll be watching for TEVA to reaffirm its 2026 guidance: revenues of $16.4–$16.8 billion (with H2 stronger than H1), non-GAAP gross margins of 54.5%–55.5%, operating expenses at ~27%–28% of sales, and non-GAAP EPS of $2.57–$2.77. Other items like finance expenses around $800 million and a tax rate of 16%–19% will matter too. The $700 million in Transformation savings targeted by 2027 (~2/3 in 2026) supports the long-term goal of 30% operating margins.
Product catalysts remain central: AUSTEDO's expansion in tardive dyskinesia (TD) and Huntington's chorea, even with Inflation Reduction Act (IRA) impacts and potential Q4 2026 demand risks from pricing changes. AJOVY and UZEDY are on paths to peak sales of $1 billion and a $1.5–$2 billion LAI franchise (pending olanzapine LAI FDA decision). Biosimilars and global generics should help offset U.S. pricing pressures.
On the balance sheet, progress toward net debt/EBITDA of 2.0x by 2027 and FCF ramping to >$3.5 billion by 2030 depends on opioid settlements ($378 million in 2026) and debt repayment. Pipeline milestones, regulatory approvals, and divestiture proceeds (e.g., API) will be critical, alongside geopolitical and currency risks—this is important because it underpins the broader strategy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TEVA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TEVA turned positive on November 03, 2026. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on TEVA as a result. In 62 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +5.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 227 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 229 of 282 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 60 cases where TEVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.123) is normal, around the industry mean (8.179). P/E Ratio (65.645) is within average values for comparable stocks, (-0.806). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.202). Dividend Yield (0.008) settles around the average of (0.046) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (181.047).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
Industry PharmaceuticalsGeneric
Advertisement